Is Cogent Biosciences, Inc. (COGT) A Good Stock To Buy Now?
Key takeaways
- Ricardo Pillai Sun, June 7, 2026 at 11:42 PM GMT+7 3 min read COGT Is COGT a good stock to buy?
- Cogent Biosciences (COGT) is a clinical-stage oncology company focused on KIT mutation-driven diseases, primarily systemic mastocytosis (SM) and gastrointestinal stromal tumors (GIST).
- Read More: 15 AI Stocks That Are Quietly Making Investors Rich
Is Cogent Biosciences, Inc. (COGT) A Good Stock To Buy Now? Ricardo Pillai Sun, June 7, 2026 at 11:42 PM GMT+7 3 min read COGT Is COGT a good stock to buy? We came across a bullish thesis on Cogent Biosciences, Inc. on X.com by @seedy19tron. In this article, we will summarize the bulls’ thesis on COGT. Cogent Biosciences, Inc. s share was trading at $34.81 as of June 1st.
Cogent Biosciences (COGT) is a clinical-stage oncology company focused on KIT mutation-driven diseases, primarily systemic mastocytosis (SM) and gastrointestinal stromal tumors (GIST). Its lead asset bezuclastinib is a highly selective type I KIT inhibitor targeting KIT D816V, positioning it as a differentiated therapy in mast-cell driven oncology. Beyond its lead program, the company is advancing a broader pipeline including a pan-KRAS(ON) inhibitor CGT1815, a JAK2 inhibitor CGT1145, and FGFR2/3 assets, expanding its optionality across solid tumors and hematologic malignancies.
Read More: 15 AI Stocks That Are Quietly Making Investors Rich